Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Das Boot who wrote (57135)	6/7/2000 12:22:00 AM
From: 2MAR$	Respond to of 122087

don't forget elon.... these faked~out , low volume manipulated, propped up, driven mrkt opens.....are craazy. Just many parotting the moves of the nasd, trying to return to former levels...because that's what market rally's do? *think i'll sleep in, get a de~caf double cappucino, read about it in the IBD , and let the whole damn thing sort it's schizophrenic self out by lunch! scmr sure was a stubborn one at the eod...cien and brcd jnpr sdli etek glw etc. F/O and infra still main plays ...as for bios probably will resume. csco as always a key....and Mr softie near break-out, LOL. go figure! :)

To: Das Boot who wrote (57135)	6/7/2000 3:41:00 AM
From: 1-DAY-TRADER	Read Replies (1) \| Respond to of 122087

ARIA <--- shorting gift brought to you by 1DT biz.yahoo.com Tuesday June 6, 5:11 pm Eastern Time Ariad Pharmaceuticals files for planned shr offer CAMBRIDGE, Mass., June 6 (Reuters) - Ariad Pharmaceuticals Inc. (NasdaqNM:ARIA - news) said on Tuesday it has filed a shelf registration statement with the Securities and Exchange Commission for a proposed common stock offering of 3.5 million shares. Once registered, these shares will be available for sale by the company when it believes that market conditions are favourable and investment opportunities arise. Lehman Brothers Inc. is acting as financial advisor to Ariad. ``We currently have approximately $34 million to fund planned operations which will allow us to achieve our product development goals,'' Chairman and Chief Executive Harvey Berger said in a statement. ``Having additional funds available at the appropriate time in the future could accelerate clinical development and regulatory approval of our regulated gene therapy products and acquisition of products, vectors, and therapeutic genes to augment our lead programmes.'' E-mail this story - View most popular stories e-mailed More Quotes and News: Ariad Pharmaceuticals Inc (NasdaqNM:ARIA - news) Related News Categories: health, IPOs, US Market News